SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0001104659-16-095085
Filing Date
2016-02-10
Accepted
2016-02-09 17:42:19
Documents
1
Group Members
BARBARA N. LUBASHBRADLEY J. BOLZONBRIAN G. ATWOODCHARLES M. WARDENDONALD B. MILDERREBECCA B. ROBERTSONROSS A. JAFFESAMUEL D. COLELLAVERSANT SIDE FUND II, L.P.VERSANT VENTURE CAPITAL II, L.P.VERSANT VENTURES II, LLCWILLIAM J. LINK

Document Format Files

Seq Description Document Type Size
1 SC 13G/A a16-3827_1sc13ga.htm SC 13G/A 437402
  Complete submission text file 0001104659-16-095085.txt   439550
Mailing Address 7999 GATEWAY BLVD SUITE 130 NEWARK CA 94560
Business Address 7999 GATEWAY BLVD SUITE 130 NEWARK CA 94560 510-293-8800
CymaBay Therapeutics, Inc. (Subject) CIK: 0001042074 (see all company filings)

IRS No.: 943103561 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-87950 | Film No.: 161401244
SIC: 2834 Pharmaceutical Preparations

Mailing Address ONE SANSOME STREET SUITE 3630 SAN FRANCISCO CA 94104
Business Address ONE SANSOME STREET SUITE 3630 SAN FRANCISCO CA 94104 650-233-7877
Versant Affiliates Fund II-A, LP (Filed by) CIK: 0001354132 (see all company filings)

IRS No.: 943410106 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A